Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMVT Immunovant	$15.86 +3.6%	$15.04	$12.72 ▼ $34.47	$2.71B	0.61	1.22 million shs	1.23 million shs
MLTX MoonLake Immunotherapeutics	$43.50 +1.2%	$40.71	$31.42 ▼ $58.26	$2.78B	1.23	384,035 shs	414,763 shs
OGN Organon & Co.	$9.89 +0.4%	$9.91	$8.01 ▼ $23.10	$2.57B	0.58	3.45 million shs	3.01 million shs
XERS Xeris Biopharma	$4.58 +0.9%	$4.57	$2.03 ▼ $6.07	$716.24M	0.71	2.00 million shs	1.88 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMVT Immunovant	+3.59%	-1.80%	+7.89%	-19.45%	-39.44%
MLTX MoonLake Immunotherapeutics	+1.16%	-1.52%	+10.97%	+6.91%	+10.15%
OGN Organon & Co.	+0.21%	-2.17%	+9.84%	-36.69%	-51.42%
XERS Xeris Biopharma	+0.88%	+4.57%	-5.95%	-15.65%	+115.02%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IMVT Immunovant	1.2066 of 5 stars	3.5	0.0	0.0	0.0	1.4	1.7	0.0
MLTX MoonLake Immunotherapeutics	1.5511 of 5 stars	3.5	0.0	0.0	0.0	1.9	2.5	0.0
OGN Organon & Co.	4.6829 of 5 stars	3.3	2.0	1.7	3.7	1.7	3.3	2.5
XERS Xeris Biopharma	4.2142 of 5 stars	3.4	2.0	0.0	4.2	3.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMVT Immunovant	2.90	Moderate Buy	$38.33	141.70% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$78.71	80.95% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	82.08% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	36.46% Upside

Current Analyst Ratings Breakdown

Latest XERS, MLTX, OGN, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	MLTX MoonLake Immunotherapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$67.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	MLTX MoonLake Immunotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$61.00
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$78.00 ➝ $80.00
5/13/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
5/5/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
4/30/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A
OGN Organon & Co.	$6.40B	0.40	$4.92 per share	2.01	$1.83 per share	5.40
XERS Xeris Biopharma	$203.07M	3.53	N/A	N/A	($0.20) per share	-22.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.43	2.64	1.03	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.30	N/A	N/A	N/A	-20.25%	N/A	-12.07%	8/6/2025 (Estimated)

Latest XERS, MLTX, OGN, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.81%	N/A	2.78%	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Latest XERS, MLTX, OGN, and IMVT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMVT Immunovant	N/A	11.16	11.16
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11
OGN Organon & Co.	16.49	1.67	1.15
XERS Xeris Biopharma	N/A	1.72	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMVT Immunovant	47.08%
MLTX MoonLake Immunotherapeutics	93.85%
OGN Organon & Co.	77.43%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
IMVT Immunovant	5.90%
MLTX MoonLake Immunotherapeutics	12.02%
OGN Organon & Co.	1.96%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMVT Immunovant	120	170.92 million	160.84 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.32 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable
XERS Xeris Biopharma	290	156.38 million	146.27 million	Optionable

XERS, MLTX, OGN, and IMVT Headlines

Recent News About These Companies

Xeris Biopharma: Great Numbers, Great Technologies, And Suitable For Long-Term Investing

June 18 at 10:17 AM | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Stock Price Up 8.4% Following Insider Buying Activity

June 18 at 1:11 AM | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 8.4% on Insider Buying Activity

June 17 at 10:18 AM | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Kevin Mcculloch Buys 25,000 Shares

June 17 at 4:49 AM | insidertrades.com

Kevin Mcculloch Purchases 25,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock

June 16 at 6:19 PM | marketbeat.com

Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings

June 9, 2025 | marketbeat.com

Leerink Partnrs Cuts Earnings Estimates for Xeris Biopharma

June 6, 2025 | marketbeat.com

Xeris Biopharma touts ambitious growth plan, promising hypothyroidism drug

June 4, 2025 | chicagobusiness.com

Mackenzie Financial Corp Buys 106,153 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

June 4, 2025 | marketbeat.com

Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

June 3, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Shares Down 5.5% - Here's What Happened

June 3, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of "Moderate Buy" from Analysts

June 3, 2025 | marketbeat.com

Nuveen Asset Management LLC Acquires 228,380 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

June 1, 2025 | marketbeat.com

Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 29, 2025 | marketbeat.com

BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 28, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street Zen

May 24, 2025 | marketbeat.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Stonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 20, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.

May 20, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS, MLTX, OGN, and IMVT Company Descriptions

Immunovant NASDAQ:IMVT

$15.86 +0.55 (+3.59%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$15.86 0.00 (-0.03%)

As of 06/18/2025 05:41 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

MoonLake Immunotherapeutics NASDAQ:MLTX

$43.50 +0.50 (+1.16%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$43.50 +0.01 (+0.01%)

As of 06/18/2025 06:12 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Organon & Co. NYSE:OGN

$9.89 +0.04 (+0.37%)

Closing price 06/18/2025 03:59 PM Eastern

Extended Trading

$9.85 -0.04 (-0.41%)

As of 06/18/2025 07:59 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Xeris Biopharma NASDAQ:XERS

$4.58 +0.04 (+0.88%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.58 0.00 (0.00%)

As of 06/18/2025 05:02 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time